No products in the cart.
Return To ShopNo products in the cart.
Return To ShopBRILINTA 90 MG, developed by AstraZeneca, is primarily prescribed to reduce the risk of heart attack and stroke in individuals with acute coronary syndromes. While it is a medication aimed at preventing blood clots, its potential uses extend beyond traditional medical applications. Athletes have shown interest in BRILINTA for its potential effects on performance and endurance, though its use should be approached with caution and under medical supervision. Understanding how it works, how to procure it safely, and its side effects is crucial for athletes considering its use.
BRILINTA contains the active ingredient ticagrelor, which acts as a potent antiplatelet agent. It works by inhibiting the ADP receptor on platelets, thereby preventing them from aggregating and forming clots. For athletes, improved blood flow may lead to enhanced endurance, allowing for better oxygen delivery to muscles. This could translate into increased performance levels during intense physical activities.
Moreover, by potentially reducing the risk of ischemic episodes during exertion, BRILINTA may help athletes optimize their training sessions and recover more effectively from intense workouts. However, it’s essential to note that the performance enhancement effects are not guaranteed and vary by individual. Consulting with healthcare professionals is pivotal to determine if the benefits outweigh any potential risks.
Acquiring BRILINTA 90 MG requires a prescription from a licensed healthcare provider. Athletes should begin by scheduling a consultation to evaluate their health needs. Online pharmacies may offer a convenient option for obtaining the medication, but it is critical to verify that they are accredited to ensure authenticity. When purchasing, look for pharmacies that provide detailed product information and customer reviews to guarantee reliability.
Once acquired, storing BRILINTA properly is essential to maintain its effectiveness. Keep the medication in a cool, dry place away from light, and ensure it is out of reach of children. Proper storage will help preserve its quality and efficacy until use.
While BRILINTA can offer advantages, it is accompanied by potential side effects that athletes need to be aware of. Common side effects include bleeding, shortness of breath, and dizziness. More serious concerns might involve severe bleeding episodes, allergic reactions, or liver dysfunction. Due to its blood-thinning properties, athletes must be particularly cautious during contact sports or activities where injury is possible.
Before utilizing BRILINTA, it is vital to discuss any existing health conditions or medications with a healthcare provider to mitigate potential interactions or complications. Regular monitoring during usage can help track any adverse reactions, ensuring safe consumption.
1. Potential enhancement of blood flow and oxygen delivery to muscles
2. Decreased risk of ischemic episodes during exercise
3. Improved endurance and recovery after high-intensity training
4. Consultative approach with healthcare providers for tailored use
5. Reliable blood clot prevention, reducing the risk of serious cardiovascular events
In conclusion, while BRILINTA 90 MG by AstraZeneca has promising aspects for athletes, caution must be exercised. Athletes should weigh the potential benefits against risks and consult with a healthcare professional to discuss individual circumstances before usage. Proper understanding and responsible use are key to optimizing athletic performance safely.
| Active substance | Ticagrelor |
|---|---|
| Water Retention | None |
| Hepatotoxicity | Low risk |
| Lab Test | Not specific, may monitor platelet function tests |
| Also known as | AZD6140 |
| Blood pressure | Can cause transient increase |
| Trade name | Brilinta, Brilique, Possia |
| FORM | 56 pills x 90 mg |
| Storage conditions | Store at room temperature away from moisture and heat |
| Chemical name | (1S,2S,3R,5R)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
| Formula | C23H28F2N6O4S |
| Substance class | Antiplatelet agent |
| Main action | Platelet aggregation inhibitor |
| Half-life | Approximately 7 to 8.5 hours |
| Dosage (medical) | Typically 90 mg twice daily |
| Dosage (sports) | Not applicable |
| Effects | Reduces the rate of stent thrombosis in patients who are at risk, decreases myocardial infarction |
| Side effects | Bleeding, dyspnea, headache, cough, hypertension, nausea |
| Use in sports | Not typically used in sports |
| Manufacturer | AstraZeneca |
€235.00
€20.00
Reviews
There are no reviews yet.